Aneuscreen

Company Overview

Snapshot

Founded in June 2017 by Assaf Harel and Haim Ezer, Aneuscreen operates with 1–10 employees. The company has raised $1.22M across two funding rounds. In August 2020, Aneuscreen secured a Seed round, with Chaim Chizik participating as an investor.

Business overview

Aneuscreen is a Health Tech & Life Sciences company focused on developing a decision-support system for the early detection and prediction of brain aneurysms. Leveraging advanced computer vision and AI techniques, their core technology identifies existing aneurysms, including those under 4mm often missed by radiologists, and classifies individuals susceptible to aneurysm development based on arterial tree morphology. The solution aims to reduce the economic burden and severe outcomes associated with subarachnoid hemorrhage, serving the healthcare industry, including hospitals and healthcare providers, with applications in diagnostics and prevention.

Company Intelligence Q&A

What is Aneuscreen's primary focus?

Aneuscreen specializes in developing a decision-support system for the early detection and prediction of brain aneurysms, utilizing advanced computer vision and AI techniques.

When was Aneuscreen founded and by whom?

Aneuscreen was founded in June 2017 by Assaf Harel and Haim Ezer.

How much capital has Aneuscreen raised to date?

Aneuscreen has raised a total of $1.22M across two funding rounds.

What was a key funding event for Aneuscreen?

In August 2020, Aneuscreen secured a Seed funding round, with Chaim Chizik participating as an investor.

What technology does Aneuscreen utilize in its solution?

Aneuscreen employs advanced computer vision and artificial intelligence techniques to analyze neuroimaging data for aneurysm detection and susceptibility classification.